PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC 50 of 8.7 nM In Vitro PDE9-IN-1 is excellent selectivity across PDE families. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PDE9-IN-1 (2.5 and 5.0 mg/kg; Oral administration; daily for 21 days) effectively recovers learning and memory function . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Unilateral common carotid artery occlusion (UCCAO) mouse model Dosage: 2.5 and 5.0 mg/kg Administration: Oral administration; daily for 21 days Result: Significantly reduced the day 6 escape latency time and increased the frequency of platform area crossings, and recovered learning and memory function. High dose group possibly improved the escape latency time of mice. Form:Solid IC50& Target:PDE9A 8.7 nM (IC 50 )
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
PDE9-IN-1
CAS number：2305087-92-5 molecular formula：C17H23FN6O2
overview
compound introduction
Specs
| Chinese alias | PDE9-合一 | ||
| English alias | - | ||
| CAS number | 2305087-92-5 | molecular formula | C17H23FN6O2 |
| molecular weight | 362.40 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
